Olympus Appoints New CEO
Names Bob White Representative Executive Officer, President, Chief Executive Officer and a New Director Candidate
TOKYO, JAPAN - April 25, 2025 ( NEWMEDIAWIRE ) - Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer and more fulfilling, today announces appointment of a Chief Executive Officer (CEO) aimed at accelerating its ongoing transformation efforts in the medtech space.
The Board of Directors has decided unanimously to appoint Bob White, a former Executive Vice President and President, Medical Surgical Portfolio for Medtronic, as a successor to Yasuo Takeuchi, Olympus' Director, Representative Executive Officer, President and CEO, effective June 1, 2025. Bob will also be proposed as a candidate for election to the Board at Olympus' General Meeting of Shareholders scheduled to be held in June 2025.
'We are pleased to name Bob to this pivotal leadership role. He possesses a wealth of experience garnered from his tenure at various esteemed organizations within the medical technology sector. I look forward to welcoming him as a leader who will bring extensive knowledge and expertise to the company,' said Yasuo Takeuchi. 'Over the course of his career, Bob has demonstrated exceptional leadership in driving both transformative growth and strategic initiatives. I am truly pleased that he is bringing this profound expertise and insight to Olympus.'
Comment from Bob White
'I am truly honored and grateful for the trust placed in me by the Board of Directors and the Nominating Committee. Olympus is an exceptional company, known for its market-leading solutions, cutting-edge technology, and remarkable people. I'm excited to bring my experience to the table and contribute to the company's ongoing success and growth. I've long admired Olympus for its rich Japanese heritage, outstanding products, and unwavering commitment to serving the needs of both clinicians and patients.'
Bob most recently served as Executive Vice President and President, Medical Surgical Portfolio for Medtronic until April 2024. Before then, he was Senior Vice President and President of Medtronic Asia Pacific, based in Singapore where he had responsibility for APAC as well as Japan. During his tenure at Covidien, he held the positions of President of Emerging Markets and President of Respiratory and Monitoring Solutions. He has seen numerous innovation programs and led several R&D initiatives and M&A transactions within complex business portfolios. His close engagement with the market and customers has enabled him to maintain a strong understanding of physician needs.
Prior to joining Medtronic, Bob held leadership positions at GE Healthcare, Merge Healthcare and Healthcare Division, IBM. Throughout his career in the medtech industry, he has played a pivotal role in improving the lives of patients around the world through the transformation of healthcare delivery.
In order to select and recommend the best candidate for the next CEO, the Nominating Committee engaged a leading executive search firm and formed an Advisory Search Committee in November 2024. After a comprehensive and rigorous search process, Olympus determined that Bob is the ideal leader among a strong pool of internal and external candidates. Bob possesses the skill set necessary to guide the next phase of Olympus' transformation, including quality and regulatory initiatives.
Bob holds a bachelor's degree in marketing from Cleveland State University and an MBA in finance from Case Western Reserve University, USA. He currently resides in Colorado and will be located in Olympus global headquarters in Tokyo, with his wife.
About Olympus
At Olympus, we are committed to Our Purpose of making people's lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit https://www.olympus-global.com/ and follow our global X account: @Olympus_Corp.
Media contact:
Mail: [email protected]
Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
SAIF Partners Files Definitive Proxy Materials in Connection with Sinovac Biotech 2025 Special Meeting of Shareholders; Nominates Ten Highly Qualified Director Candidates to the Board
Sends Open Letter to Sinovac Shareholders Calling for a New Board to End Years of Chaos at Sinovac SAIF Nominees Will Work to Resolve Costly Legal Battles, Take Action to Resume Stock Trading after Six-Year Halt, and Facilitate Distribution of Cash That Rightfully Belongs to Shareholders Urges Sinovac Shareholders to VOTE the GOLD Proxy Card FOR the Election of SAIF's Director Nominees BEIJING, June 16, 2025--(BUSINESS WIRE)--SAIF Partners IV L.P., ("SAIF Partners"), the largest single investor in Sinovac Biotech Ltd. ("Sinovac" or the "Company"), beneficially owning approximately 15% of the outstanding common shares, today announced that it has filed a definitive proxy statement for the election of ten director nominees to Sinovac's Board of Directors (the "Board") in connection with the special meeting of the shareholders of the Company to be held on Tuesday, July 8, 2025 at 8 p.m. Atlantic Standard Time (Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time), and at any adjourned, postponed, continued, or rescheduled meeting thereof (the "Special Meeting"). Additionally, SAIF Partners issued an open letter to its fellow Sinovac shareholders outlining its belief that new highly qualified directors are required to effectively resolve the significant challenges Sinovac currently faces and deliver value for all shareholders. In the letter, SAIF details how the Board has not effectively guided Sinovac after the significant chaos of the past several years, including, among other issues, strategic missteps, costly and distracting legal battles, a stock that does not trade, and a large amount of cash that the Company is inexplicably retaining rather than distributing it to shareholders as they should. If elected, SAIF Partners' nominees will work with management to develop a plan to address these issues and bring disciplined corporate governance, proper capital allocation, strategic foresight and operational excellence to Sinovac. SAIF Partners has outlined the most critical priorities for Sinovac that their nominees would seek to address if elected, including declaring additional dividends, resuming trading of common shares and resolving shareholder disputes. The full text of the letter is below. June 16, 2025 Dear Fellow Sinovac Shareholder: As the largest single investor and a long-term shareholder in Sinovac Biotech Ltd. ("Sinovac" or the "Company"), beneficially owning approximately 15% of the outstanding common shares, SAIF Partners ("SAIF") believes deeply in the Company's products and tremendous potential to create long-lasting value for all shareholders. However, Sinovac's Board of Directors (the "Board") has not effectively guided Sinovac after the significant chaos of the past several years, including, among other issues, strategic missteps, costly and distracting legal battles, a stock that does not trade, and a large amount of cash that the Company is inexplicably retaining rather than distributing it to shareholders as they should. The Board has done nothing to address these issues and only began to acknowledge them after we forced Sinovac to hold a special meeting to replace directors. Simply put, the status quo is not working. Sinovac desperately needs new and experienced directors dedicated to putting Sinovac back on the right track through disciplined corporate governance, proper capital allocation, strategic foresight and operational excellence – and acting in the best interests of ALL Sinovac shareholders. As such, SAIF is nominating highly qualified candidates for election to the Board at the special meeting of shareholders to be held July 8, 2025. We have taken this important action to address key issues at Sinovac that, if elected, will be top priorities for our nominees, including: 1. Declaration of Additional Dividend. We believe there are billions of US dollars of available cash in Sinovac's accounts and that Sinovac can and should pay more dividends to shareholders in addition to the $55.00 per share special dividend declared by the Board on April 1, 2025, which would not have been announced without our engagement. Further, dividends have been paid from Sinovac subsidiaries, but not to shareholders. Our nominees will determine, in close collaboration with management, on the appropriate allocation of retained earnings and facilitate the distribution of long-overdue returns to all shareholders. 2. Resumption of Trading of Common Shares of the Company. Sinovac shares have not traded for more than six years, denying shareholders the liquidity they deserve. Our nominees will take immediate steps to address compliance issues and work expeditiously towards the resumption of trading of the Company's shares. 3. Resolution of Shareholder Disputes and Unlocking the Company's Full Potential. Sinovac has been entrapped in endless disputes and prolonged lawsuits since 2018. We are concerned that the series of legal disputes started recently will cause more crisis and destruction to the interests of the Company and its shareholders. Our nominees will engage with these shareholders to amicably resolve ongoing disputes, eliminate divisions, and foster alignment among shareholders in order to focus on Sinovac's core mission, and drive growth and value. 4. Strategic Realignment for Shareholder Value Creation. Sinovac's Board does not currently have a strategic plan in place that reflects the realities of the current market environment and positions the Company to capitalize on emerging opportunities in the biopharmaceutical sector. Our nominees will work closely with Sinovac management to develop a business strategy with clear operational objectives to drive long-term value for all shareholders. A NEW BOARD IS DESPERATELY NEEDED TO RESTORE CREDIBILITY AND ENSURE SHAREHOLDER VALUE IS NOT FURTHER ERODED Sinovac shareholders deserve a Board that is unbiased in its decision making and dedicated to acting on behalf of all shareholders rather than for a select few. Presently, all but one member of the Board are representatives of 1Globe and OrbiMed, whose influence far exceeds their respective 9.5% and 3.8% ownership stakes in Sinovac. We believe our nominees – who represent a broad base of major Sinovac shareholders including Weidong Yin (the CEO and founder of the Company), SAIF Partners, Vivo Capital, CDH Investment, Advantech Capital, and 1Globe – will comprise a well-balanced and diversified Board with extensive industry knowledge, experience and insights necessary to end costly and distracting internal strife, and execute a clear strategic plan that maximizes sustainable, long-term value for ALL shareholders. Certain of our nominees have key management experience at Sinovac and will work closely with the Company management team to drive long-term value for all shareholders. We urge you to join us and vote the GOLD proxy card in support of our highly qualified nominees who will make the changes necessary to help Sinovac realize its tremendous potential and build the value of Sinovac for all shareholders. Please vote on the GOLD proxy card TODAY! Sincerely, SAIF Partners YOUR VOTE IS IMPORTANT, NO MATTER HOW MANY OR HOW FEW SHARES YOU OWN! Please vote today by telephone or via the Internet by following the easy instructions on the GOLD proxy card. If you have any questions or require assistance in authorizing a proxy or voting your common shares, please contact: Sodali & Co 430 Park Avenue, 14th Floor New York, NY 10022 Call Toll-Free in North America: (800) 662-5200 Outside of North America Call Collect: (203) 658-9400 Email: SAIF@ Please do not return any proxy card you may receive from the Company or otherwise authorize a Company's proxy to vote your common shares at the special meeting, not even as a protest vote. If you have already sent a proxy card to the Company or otherwise authorized a Company's proxy to vote your common shares at the special meeting, it is not too late to change your vote by using the enclosed GOLD proxy card. Only your latest dated proxy will be counted. About SAIF PartnersSAIF Partners is a leading Asian private equity firm with cumulative assets under management of over $4 billion. SAIF Partners is an active lead investor working closely with its portfolio companies to develop their business both organically and through acquisitions, seeking synergistic cooperation among them, as well as enhancing shareholder value via promotion of good corporate governance and best management practices. Additional Information and Where to Find It This communication may be deemed to be solicitation material in respect of SAIF Partners' nomination of ten director nominees to Sinovac's Board. In connection with such solicitation, SAIF Partners mailed the definitive proxy statement and proxy card to shareholders of Sinovac with respect to the Special Meeting to be held in connection with the election of directors to Sinovac's Board. The definitive proxy statement mailed by SAIF Partners is also filed as Exhibit 1 to its Schedule 13D/A filed on or about June 16, 2025. SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY WILL MAIL AND FILE WITH THE SEC IN CONNECTION WITH THE SINOVAC SPECIAL MEETING, INCLUDING ANY DOCUMENT INCORPORATED BY REFERENCE THEREIN, CAREFULLY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE DIRECTOR NOMINEES AND THE SPECIAL MEETING AND RELATED MATTERS. Sinovac's shareholders may obtain, free of charge, the definitive version of the proxy statement, any amendments or supplements thereto, and any other relevant documents mailed by SAIF Partners in connection with the Special Meeting at View source version on Contacts Media Contacts Jonathan Gasthalter/Mark Semer/Grace CartwrightGasthalter & Co.+1 (212) 257 4170SAIF@ Investor Contacts Paul Schulman/Bill Dooley/Jon EylSodali & Co.+ 1 (203) 658-9400SAIF@
CNBC
an hour ago
- CNBC
Why a pacifist Japan seems to be doubling down on arms exports
Japan, renowned for its pacifist constitution, is now setting its sights on the global arms exports market. Defense Minister Gen Nakatani earlier this month told Nikkei that he wanted to promote Japan's defense exports, signaling a clear shift in the country's arms policy, which has so far been largely restricted to catering to the Japan Self-Defense Forces, or JSDF. Prime Minister Shigeru Ishiba has also signaled sharper focus on the defense sector and became the first sitting prime minister to attend DSEI Japan, the country's largest defense exhibition. While the shift in stance comes at a time when global defense spending has been on the rise, Japan's motivations are linked more to its security concerns than profiting from the surge in global arms demand, experts told CNBC. The biggest reason behind this shift is to deepen ties and increase interoperability of Japanese forces with allies and partners, said Rintaro Inoue, research associate at the Institute of Geoeconomics, a Tokyo-based think tank. By exporting its arms abroad, a country is able to improve interoperability with the purchasing parties by standardizing maintenance processes for hardware and creating joint training opportunities. "This rationale has been the main pillar after Prime Minister [Shinzo] Abe created the concept of 'proactive contribution to peace' in 2013 which aims to deepen cooperation with other Western countries in this area, and especially in security fields," he said. When the late Abe was in office, he led efforts to revise the interpretation of Article 9 of Japan's constitution to allow the JSDF to more actively contribute to international peacekeeping efforts and defend allies. Japan also wants to develop its defense industrial base, which had been in "very poor conditions" before the country moved to increase its defense budget in 2022, Inoue said. Exports will allow it to achieve the economies of scale needed to make domestic production more viable. Instead of investing in Japan's domestic defense base, the country has largely purchased weapons from the U.S., such as the F-35 fighter jets and SPY-7 radar systems. "This created a severe situation among the defense industry based in Japan, and several companies have left the industry, especially in the supply chain," Inoue said. In 2023, more than 100 companies were reported to have left the defense industry in the past 20 years. Naoko Aoki, political scientist at U.S.-based policy think tank RAND, said that Japanese defense firms have traditionally operated with limited domestic demand from the JSDF. Being able to export defense items means that companies would have a bigger customer base, helping them develop production capacities, lower costs and have more flexibility. "Even if the JSDF needed more of, for example munitions, these companies would not be eager to invest in new facilities to produce more of them, if they think that is a one-time request. If there were more stable demand at a higher level, however, they can justify the investment," Aoki said. As of 2024, Japan's arms exports stood at 21 million TIV — just 0.1% of global arms exports — according to the Stockholm International Peace Research Institute. The TIV or trend-indicator value is a measure of the volume of international transfers of major conventional weapons. In comparison, neighboring South Korea exported 936 million TIV in 2024, with 3.3% of global arms exports, while TIV for China, the largest Asian arms exporter from 2020-2024 stood at 1.13 billion, accounting for 3.9% of global shipments. Defense is attractive as a growth sector, according to veteran investor David Roche, strategist at Quantum Strategy. "Demand will exceed supply for a decade,he said. So, building domestic capacity is of paramount importance. Roche said that if nations such as Japan stay dependent on the U.S., the Trump administration's more transactional approach will oblige them to pay for much more of their own defense, or defense equipment supplied by the pointed to U.S. Defense Secretary Pete Hegseth's speech during the 2025 Shangri-La Dialogue, earlier this month: "We ask — and indeed, we insist — that our allies and partners do their part on defense ... NATO members are pledging to spend 5% of their GDP on defense, even Germany." "So it doesn't make sense for countries in Europe to do that while key allies in Asia spend less on defense in the face of an even more formidable threat, not to mention North Korea," Hegseth added. "If they distrust the U.S. to honor its treaty engagements, then individual nations must ensure their own security and spend a lot of money doing so," Roche said. Japan in 1967 adopted "Three Principles on Arms Exports" that restricted arms exports, and later expanded those principles to a practically impose an across-the-board ban on arms exports, except for transfers of military technologies to the U.S. The country relaxed this stance under Abe, with former Prime Minister Fumio Kishida easing the curbs further in 2023. The most recent changes allow defense equipment manufactured in Japan under license from foreign defense firms, including finished products, to be exported to the licensing country and from there to third countries. For example, Japan agreed in late 2023 to manufacture — under license — and export Patriot interceptor missiles to the U.S., whose stockpiles were depleted after supplying these missiles to Ukraine. Neighbor South Korea has seen increasing global interest in its arms industry and is striving to become a major global arms supplier. Will Japan be able to compete? Experts says that Japan has the knowledge, skills and technology to be a major arms supplier, but IOG's Inoue warns that Japan may face manufacturing issues due to its falling population and growing proportion of seniors. "I think it's very difficult for Japan to once again focus into manufacturing jobs," he said. RAND's Aoki pointed to still-strict regulations. "Japan has the technical capacity to do many things," but as export regulations remain severe, it will use exports mainly as a tool to strengthen its defense industrial base and defense relations with like-minded countries, particularly the U.S.
Yahoo
4 hours ago
- Yahoo
Brookfield Renewable Corporation Announces Results of Annual Meeting of Shareholders
BROOKFIELD, NEWS, June 16, 2025 (GLOBE NEWSWIRE) -- Brookfield Renewable Corporation (the 'Corporation') (TSX, NYSE: BEPC) today announced that all eight nominees proposed for election to the board of directors of the Corporation by holders of class A exchangeable subordinate voting shares ('Exchangeable Shares') and holders of class B multiple voting shares ('Class B Shares') were elected at the Corporation's annual meeting of shareholders held on June 16, 2025 in a virtual meeting format and that Ernst & Young LLP have been re-appointed as the corporation's external auditor. Detailed results of the vote for the election of directors are set out below. In accordance with the Corporation's articles, each Exchangeable Share was entitled to one vote per share, representing a 25% voting interest in the Corporation in the aggregate, and the Class B Shares were entitled to a total of 434,657,409 votes in the aggregate, representing a 75% voting interest in the Corporation. The following is a summary of the votes cast by holders of Exchangeable Shares and Class B Shares, voting together as a single class, in regard to the election of the eight directors: Director Nominee Votes For % Votes Withheld % Jeffrey Blidner 482,820,764 91.31 % 45,962,036 8.69 % Sarah Deasley 527,800,142 99.81 % 982,659 0.19 % Nancy Dorn 520,643,761 98.46 % 8,139,040 1.54 % Eleazar de Carvalho Filho 527,545,478 99.77 % 1,237,321 0.23 % Randy MacEwen 527,645,430 99.78 % 1,137,371 0.22 % Lou Maroun 515,462,819 97.48 % 13,319,981 2.52 % Stephen Westwell 520,624,339 98.46 % 8,158,461 1.54 % Patricia Zuccotti 527,675,815 99.79 % 1,106,986 0.21 % A summary of all votes cast by holders of the Exchangeable Shares and Class B Shares represented at the Corporation's annual meeting of shareholders is available on SEDAR+ at Brookfield Renewable Brookfield Renewable operates one of the world's largest publicly traded platforms for renewable power and sustainable solutions. Our renewable power portfolio consists of hydroelectric, wind, utility-scale solar and storage facilities and our sustainable solutions assets include our investment in a leading global nuclear services business and a portfolio of investments in carbon capture and storage capacity, agricultural renewable natural gas, materials recycling and eFuels manufacturing capacity, among others. Investors can access the portfolio either through Brookfield Renewable Partners L.P. (NYSE: BEP; TSX: a Bermuda-based limited partnership, or Brookfield Renewable Corporation (NYSE, TSX: BEPC), a Canadian corporation. Brookfield Renewable is the flagship listed renewable power and transition company of Brookfield Asset Management, a leading global alternative asset manager headquartered in New York, with over $1 trillion of assets under management. Contact information: Media: Investors: Simon Maine Alex Jackson +44 7398 909 278 +1 (416) 649-8172 Sign in to access your portfolio
